The latest update is out from Emergent Biosolutions ( (EBS) ).
Emergent BioSolutions reported its financial results for the fourth quarter and full year 2024, highlighting a total revenue of $1.04 billion for the year. Despite a net loss of $31.3 million in Q4, this marked a 37% improvement from the previous year. The company achieved a significant increase in adjusted EBITDA, reaching $183.1 million for the year compared to a loss in 2023, and is guiding for an adjusted EBITDA between $150 million and $200 million in 2025. Strategic actions, including debt repayment and asset divestitures, have strengthened its financial position. The company also received substantial contract awards and FDA approval for expanding the use of ACAM2000®.
More about Emergent Biosolutions
Emergent BioSolutions Inc. operates in the biopharmaceutical industry, focusing on products that address public health threats. Its primary offerings include medical countermeasures against chemical, biological, radiological, and nuclear threats, as well as emerging infectious diseases. The company is known for products like NARCAN® Nasal Spray and BioThrax® (Anthrax Vaccine Adsorbed), with a significant market focus on government and defense contracts.
YTD Price Performance: -27.17%
Average Trading Volume: 1,054,235
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $405.3M
For a thorough assessment of EBS stock, go to TipRanks’ Stock Analysis page.